Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC
2 Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers
3 Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
4 Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape
5 Regorafenib Plus Nivolumab Limits Tumor Growth In Gastric and Colorectal Cancers
6 Ahn Expands on Advances Made With Actionable Alterations in CRC
7 Individualized Treatment Is Key for mCRC
8 A Growing Number of Immunotherapeutics Are Taking Hold in CRC
9 Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer
10 Oligometastatic Disease Status May Impact Treatment Decisions in mCRC
11 Dr. Kim on Immunotherapy in CRC
12 Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
13 Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
14 Guest Commentary: 'Intriguing' ASCO data highlights new excitement in colorectal cancer
15 Shaping the GI Cancer Treatment Landscape: The Power and Potential of Kinase Inhibition
16 Bayer, BMS, Ono team up to investigate Stivarga, Opdivo combo
17 Bristol-Myers Squibb 2019: More of everything – PharmaLive
18 Bayer Data at ASCO 2019 Highlights Commitment to Evolving the Cancer Treatment Paradigm